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Abstract The association between nonfasting triglycerides
and cardiovascular disease (CVD) has recently been actual-
ized. The aim of the present study was to investigate nonfa-
stingtriglyceridesasapredictorofCVDmortalityinmenand
women. A total of 86,261 participants in the Norwegian
Counties Study 1974–2007, initially aged 20–50 years and
freeofCVDwereincluded.Weestimatedhazardratios(HRs)
for deaths from CVD, ischemic heart disease (IHD), stroke
and all causes by level of nonfasting triglycerides. Mean fol-
low-upwas27.0 years.Atotalof9,528mendied(3,620from
CVD, 2,408 IHD, 543 stroke), and totally 5,267 women died
(1,296CVD,626IHD,360stroke).AfteradjustmentforCVD
riskfactorsotherthanHDL-cholesterol,theHRs(95%CI)per
1 mmol/l increase in nonfasting triglycerides were 1.16
(1.13–1.20), 1.20 (1.14–1.27), 1.26 (1.19–1.34) and 1.09
(0.96–1.23) for all cause mortality, CVD, IHD, and stroke
mortality in women. Corresponding ﬁgures in men were 1.03
(1.01–1.04), 1.03 (1.00–1.05), 1.03 (1.00–1.06) and 0.99
(0.92–1.07). In a subsample where HDL-cholesterol was
measured (n = 40,144), the association between CVD mor-
tality and triglycerides observed in women disappeared after
adjustment for HDL-cholesterol. In a model including the
Framingham CHD risk score the effect of triglycerides dis-
appeared in both men and women. In conclusion, nonfasting
triglycerideswereassociatedwithincreasedriskofCVDdeath
forbothwomenandmen.Adjustmentformajorcardiovascular
risk factors, however, attenuated the effect. Nonfasting tri-
glycerides added no predictive information on CVD mortality
beyond the Framingham CHD risk score in men and women.
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Blood samples for measurements of triglyceride levels are
typicallyobtainedinthefastingstate,andincreasedlevelsof
fastingtriglycerideshavebeenassociatedwithincreasedrisk
of cardiovascular disease (CVD) in a number of studies
[1–4]. Atherosclerosis is suggested to be a postprandial
phenomenon [5, 6]. Recent prospective cohort studies sug-
gestthattheassociationwithcoronaryheartdisease(CHD)is
stronger for nonfasting than fasting triglycerides [7, 8], and
possibly also for stroke [9]. In the Women’s Health Study,
nonfasting triglycerides were associated with incident car-
diovascular events, independent of other risk factors, lipids,
and markers of insulin resistance, whereas weaker associa-
tionswerefoundforfastinglevels[7].Theassociationswere
particularlystrongforsamplesdrawn2–4 haftermeals.This
corresponds to peak levels of triglycerides and remnant
particles at 4 h after meal consumption, with a gradually
decline thereafter [8]. Elevated levels of postprandial tri-
glycerides may indicate a high content of remnant lipopro-
teins derived from triglyceride rich chylomicrons [5].
Remnant lipoproteins can enter the arterial wall, and con-
tribute to the formation of foam cells and thus cause ath-
erosclerosis [10]. Measurements in the postprandial state
include these remnant lipoproteins.
The associations between triglycerides and cardiovas-
cular risk have been reported to be stronger in women than
in men in both fasting and nonfasting states [1, 8]. The
Norwegian Counties Study is a prospective cohort study
comprising three consecutive cardiovascular screenings
performed between 1974 and 1988 in three Norwegian
counties including over 90,000 individuals. Two earlier
papers from this cohort study (in 1989 and 1993), found
nonfasting triglycerides to be an independent risk factor for
cardiovascular death in women [11], but not in men [12].
These papers had short follow-up, and used data only from
the ﬁrst screening. With additional data from the two latter
screenings and a substantially longer follow-up, we study
the association between nonfasting levels of triglycerides
and cardiovascular mortality risk, including stroke, in this
large cohort of women and men. In a subsample from the
second screening, we also study the effect of adjustment for
HDL-cholesterol and Framingham risk score.
Methods
The Norwegian Counties Study
Three consecutive cardiovascular screenings (screenings I,
II, and III) in the three Norwegian counties Oppland, Sogn
og Fjordane, and Finnmark, were carried out in 1974–78,
1977–83, and 1985–88, respectively (Fig. 1). A detailed
overview of the invited age groups and attendance
according to survey and county has previously been
described [13]. Brieﬂy, in screening I all residents aged
35–49 years, and a random sample aged 20–34 years, were
invited. In screening II, individuals from the previous
screening still residing in the county were re-invited, in
addition to a random sample aged 20–39 years. All
inhabitants aged 40–54 years (40–62 years in Finnmark)
and samples of previously invited, were invited to
screening III. The attendance at each screening was 88, 88
and 84%. The methods and results from the ﬁrst and second
screening have been described in detail [14–16].
Data collection
Investigations according to standardized methods were
carried out by mobile screening teams [14]. All invited
persons were asked to ﬁll in the main questionnaire at
home and bring it to the screening station. Then, according
to the protocol, a trained nurse checked it for omissions and
inconsistencies. The questionnaire covered among other
things, history of previous cardiovascular disease and
Screenings I, II, and III in three Norwegian counties:
Finnmark: I:1974-75, II: 1977-78, III: 1987-88
Sogn og Fjordane: I:1975-76, II: 1980-81, III: 1985-86 
Oppland: I:1976-78, II: 1981-83, III: 1986-88
Selected first attendance for each 
participant:
Number attended screening II in 
Sogn og Fjordane or Oppland:
Screening I n = 57 709
Screening II n = 11 046
Screening III n = 23 363
Total sum n = 92118
n= 45 875
Study sample, age 20-50:
n= 86 241 (Table 1)
Exclusions*
Missing data on 
Exclusions*
covariates
Missing data on 
covariates
Sub sample with HDL, age 20-55 at 
screening II:
n= 40 143 (Tables 5-6)
Subjects aged < 40 years
Study sample, multivariable analyses,
age 20-50:
n= 83 970 (Tables 2-4)
Sub sample Framingham risk, age 40-
55 at screening II:
n= 33 123 (Table 7) 
Fig. 1 Flow chart illustrating how study samples were obtained from
the three screenings. *Exclusions: Participants reporting a history of
myocardial infarction, angina, stroke, diabetes, use of nitroglycerine
or blood pressure reducing drugs, outside age range, extreme/missing
triglyceride values or incomplete data on observation time
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123disease symptoms, current medication (blood pressure
lowering or nitroglycerine) level of leisure time physical
activity, and smoking habits. Menopause was registered by
personal interview. Moreover, a simple clinical examina-
tion was performed. Body weight (kilograms) and height
(cm) were measured with the participants wearing light
clothing without shoes. Body mass index (BMI) was
computed as weight/height
2 (kg/m
2). In screenings I and II,
systolic and diastolic blood pressure (mm Hg) were mea-
sured with a mercury sphygmanomenter (ERKA, Kallmeyer
Medizintechnik GmbH & Co KG, Bad To ¨lz, Germany).
Two readings were recorded, and the second was used.
A Dinamap 845XT instrument (Criticon Inc., Tampa,
Florida, USA) was used at screening III. Three different
readings were made with one-minute intervals, and the
mean of the two last measurements was used. In all three
screenings a nonfasting venous blood sample was drawn.
The analyses were performed at the Central Laboratory,
Ulleva ˚l Hospital, Oslo, Norway. Total cholesterol and tri-
glyceride analyses were carried out in all screenings,
whereas HDL-cholesterol was analyzed at screening II
only. The HDL-cholesterol measurements for Finnmark
were performed in samples that had been frozen, in con-
trast to samples from Oppland and Sogn og Fjordane, thus
only the HDL-cholesterol values from the to latter counties
were used in the present study. HDL-cholesterol was ana-
lysed by enzymatic methods [17]. For total cholesterol
and triglycerides, non-enzymatic methods were used in
screening I (all counties). The accuracy of the methods
have been described in detail previously [12, 14]. In
screening II, non-enzymatic methods were used on samples
from Finnmark, whereas enzymatic methods were used on
samples from Sogn og Fjordane and Oppland [17]. Enzy-
matic methods were used in screening III. Triglycerides
and cholesterol values from non-enzymatic analyses were
corrected to values compatible with enzymatic methods
according to the formulas: Triglyceride (new method)
=0.90* triglyceride (old method) - 0.11 and cholesterol
(new method) = 0.92* cholesterol (old method) ? 0.03.
The formulas were evolved after an extensive test program
comparing the old and new method [16].
Study samples
For the main analyses in the present study we have used
data from the ﬁrst attendance for each participant, either
screenings I, II, or III (Fig. 1). Participants reporting a
history of myocardial infarction, angina, stroke, diabetes,
or use of nitro-glycerine or blood pressure reducing drugs,
were excluded (n = 3,965). The analyses were further
limited to the age group 20–50 years (n = 1,850 exclu-
ded), as the majority of the participants were in this
age range. Subjects missing triglyceride measurement
(n = 42), with extreme triglyceride levels (triglycer-
ides\0.2 mmol/l or triglycerides[20 mmol/l, n = 18)
or subjects with incomplete data on observation time
(n = 2) were excluded, giving a sample of 86,241 partic-
ipants (42,600 women and 43,641 men), aged 20–50 years
and initially free of cardiovascular disease. After further
exclusions of records with missing data on covariates, the
main study sample consisted of 83,970 participants (41,317
women and 42,653 men) (Fig. 1).
To allow for adjustments for HDL-cholesterol, additional
analyseswereconductedinsubjectsparticipatinginscreening
IIinOpplandandSognogFjordane.Participantswere5 years
olderatscreeningII,thusweincludedagegroup20–55 years.
By using the same criteria as for the main study sample
described above, 40,143 participants (20,293 women and
19,850 men) free of cardiovascular disease were eligible for
these analyses (Fig. 1, sub sample with HDL). Analyses
including Framingham risk were restricted to 33,123 partici-
pants aged 40–55 years at baseline (16,805 women and
16,318 men) (Fig. 1, sub sample Framingham risk).
Deﬁnition of endpoints
The linkage to the Norwegian Causes of Death Registry
was ensured by the unique 11-digit identiﬁcation number
of all Norwegian citizens. This linkage was approved by
the Norwegian Data Inspectorate. Deaths were classiﬁed
according to the 8th, 9th or 10th revision of the Interna-
tional Classiﬁcation of Disease (ICD). We studied CVD
(ICD 8 (1974–1985) codes 390–344.1, 444.3–458, 782.4,
ICD 9 (1986–1995) codes 390–459, ICD 10 (1996–) codes
I00–I99), ischemic heart disease (IHD) (ICD 8–9 codes
410–414, ICD 10 codes I20–I25), stroke (ICD 8–9 codes
430–438, ICD 10 codes I60–I69), and all cause mortality.
End of follow-up was 31 December 2007.
Statistical analyses
Cox proportional hazards regression was applied with
attained age as the time scale. The number of person years
was calculated from the date of examination to the date of
death, emigration or 31.12.2007, whichever came ﬁrst.
Triglycerides were categorized according to quintiles
(separately for men and women) and modelled as dummy
variables. To test for trend, triglycerides categories were
entered as an ordinal variable. We adjusted for known
CVD risk factors; total cholesterol, systolic blood pressure,
BMI, daily smoking (yes, no), time since last meal (less
than 1 h, 1–2 h, 2–4 h, 4 h or more), leisure time physical
activity (sedentary, moderate, intermediate/intensive), and
menopausal status for women (yes, no). The upper two
categories for time since last meal and physical activity
were collapsed due to small numbers. Additional
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123adjustments for HDL-cholesterol were performed for sub-
jects in the sub-sample from screening II. Furthermore,
individual Framingham risk scores were calculated
according to Anderson et al. [18] (only for participants
C40 years), and added as a covariate in the analyses on the
sub-sample. Framingham risk score includes the risk fac-
tors total cholesterol, HDL-cholesterol, smoking (no, yes),
age, systolic blood pressure and diabetes (no, yes). Statis-
tical analyses were performed on subjects with complete
information on all covariates.
The proportional hazards assumption was examined by
Schoenfeld residuals. We tested interaction effects between
triglycerides and gender, time since last meal, cholesterol,
BMI, and smoking, with triglycerides as a continuous
variable. The linearity assumption for triglycerides was
assessed by comparing adjusted models having only a
linear term with models having linear and higher order
polynomial terms (quadratic and cubic terms). The likeli-
hood ratio test was used for model comparison.
A total number of 51,931 subjects had measurements
of triglycerides both in screenings I and II, approxi-
mately 5 years apart. The partial correlation coefﬁcients
(R) between the two measurements, adjusted for age, were
estimated to 0.50 for men and 0.51 for women. These
values can be used to assess regression dilution for age-
adjusted hazard ratios [19]. HRs adjusted for regression
Table 1 Baseline [Baseline values are data from ﬁrst attendance for individuals participating in at least one of the screenings] characteristics of
86,241 participants (42,600 women and 43,641 men) from the Norwegian Counties Study by quintiles of triglycerides in the main study sample
(age 20–50 at baseline)
Quintile of nonfasting triglycerides All
12345
Women
Triglycerides,
median
(range),
(mmol/l)
0.66
(0.21–0.79)
0.90
(0.80–1.01)
1.13
(1.02–1.27)
1.46
(1.28–1.70)
2.16
(1.71–18.72)
1.13
(0.21–18.72)
No. of participants 8,585 8,303 8,576 8,654 8,482 42,600
Age, mean (SD), year 37.8 (7.1) 39.2 (6.9) 39.7 (6.8) 40.0 (6.9) 40.1 (6.7) 39.5 (6.9)
Total cholesterol, mean
(SD),
(mmol/l)
5.37 (0.96) 5.76 (1.01) 5.98 (1.10) 6.19 (1.14) 6.66 (1.34) 5.99 (1.20)
Systolic blood pressure,
mean (SD), (mm Hg)
125 (15) 126 (15) 127 (16) 129 (16) 132 (18) 128 (16)
Diastolic blood pressure,
mean (SD), (mm Hg)
77 (8) 78 (10) 78 (10) 79 (11) 81 (11) 79 (11)
BMI, mean (SD), (kg/m
2) 22.8 (3.0) 23.4 (3.3) 23.9 (3.6) 24.4 (3.9) 26.0 (4.7) 24.1 (3.9)
Post-menopausal (%) 4.1 6.3 7.5 8.9 12.3 7.8
Smoking (%) 31.8 36.9 40.5 43.0 48.4 40.1
Physical inactivity (%) 18.1 20.3 20.5 22.2 24.8 21.8
Time since meal, mean
(SD)
2.75 (0.99) 2.61 (0.98) 2.56 (0.97) 2.45 (0.95) 2.42 (0.93) 2.56 (0.97)
Men
Triglycerides,
median
(range),
(mmol/l)
0.89
(0.21–1.10)
1.29
(1.11–1.47)
1.69
(1.48–1.93)
2.23
(1.94–2.64)
3.41
(2.65–19.35)
1.69
(0.21–19.35)
No. of participants 8,754 8,596 8,900 8,659 8,732 43,641
Age, mean (SD), year 38.2 (7.5) 39.1 (7.1) 39.8 (6.8) 40.2 (6.5) 40.7 (6.1) 39.6 (6.9)
Total cholesterol, mean
(SD),
(mmol/l)
5.56 (1.08) 5.92 (1.14) 6.13 (1.19) 6.42 (1.23) 6.86 (1.32) 6.18 (1.27)
Systolic blood pressure,
mean (SD), (mm Hg)
133 (15) 134 (15) 135 (15) 136 (15) 138 (15) 135 (14.9)
Diastolic blood pressure,
mean (SD), (mm Hg)
81 (11) 82 (11) 82 (11) 83 (11) 85 (11) 82 (11)
BMI, mean (SD), (kg/m
2) 23.8 (2.6) 24.3 (2.6) 24.7 (2.8) 25.3 (2.9) 26.5 (3.2) 24.9 (3.0)
Smoking (%) 47.7 51.1 51.9 53.1 55.5 51.9
Physical inactivity (%) 16.0 17.5 18.1 19.2 21.5 18.5
Time since meal, mean
(SD)
2.77 (1.10) 2.51 (1.06) 2.38 (1.02) 2.29 (1.00) 2.26 (0.98) 2.44 (1.05)
Abbreviations BMI body mass index, SD standard deviation
SI conversion factors To convert triglycerides to mg/dl, divide values by 0.013; and cholesterol to mg/dl, divide values by 0.0259
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123dilution are calculated as HRd = exp (lnHR/R), where HR
is the age-adjusted hazard ratio.
Statistical analyses were performed using STATA ver-
sion 10.0 (STATA Corp. TX, USA).
Results
The study included 42,600 women and 43,641 men aged
20–50 years at inclusion, with a mean follow-up of
27.0 years (range 0.01–33.8). Women had lower levels of
triglycerides compared to men, medians (range) triglycer-
ides were 1.13 (0.21–18.72) mmol/l and 1.69 (0.21–19.35)
mmol/l, respectively (Table 1). Mean age, total cholesterol,
systolic and diastolic blood pressure, BMI, the proportions
of smokers and physically inactive individuals increased
over the quintiles for both women and men. The proportion
of post-menopausal women also increased with increasing
quintiles of triglycerides. The majority of the blood sam-
ples (98.2%) were drawn less than 8 h after the last meal
(data not shown), and can therefore be considered nonfa-
sting samples. The levels of triglycerides were highest in
the category measured less than 1 h after meal with a
gradual decline thereafter (data not shown).
During follow-up, 5,267 women and 9,528 men died
(Tables 2, 3). Of these, 1,296 women and 3,620 men died
from CVD, 626 women and 2,408 men from IHD, and 360
women and 543 men from stroke. Mean age at death was
63.4 years (range 23.5–82.9). Mortality rates from all
causes, CVD and IHD, increased over quintiles in both
women and men, and from stroke in women only. In
women the mortality rates were markedly higher in the ﬁfth
quintile. Signiﬁcant interactions between triglycerides and
gender were found for all endpoints, and all analyses were
thus stratiﬁed by gender. In age-adjusted analyses, signif-
icant positive trends were found for all endpoints, except
for stroke in men (Tables 2, 3). The estimated HRs were
highest for CVD and IHD, and higher in women than men.
In multivariable analyses, the associations were attenu-
ated in both women and men (Tables 2, 3). Signiﬁcantly
elevated HRs were found in women in the ﬁfth quintile for
all cause, CVD, and IHD deaths (P for trend\0.001) and
for stroke (P for trend 0.03). In men the positive trend
disappeared for all cause deaths after multivariable
Table 2 Association between triglycerides and risk of death from all causes, CVD, IHD, and stroke in 41,317 women in the main study sample
(age 20–50 at baseline)
Quintile of nonfasting triglycerides, range (mmol/l) P for trend
12 3 4 5
0.21–0.79 0.80–1.01 1.02–1.27 1.28–1.70 1.71–18.72
No. of participants 8,343 8,082 8,350 8,385 8,157
All cause deaths
No. of cases 663 842 1,056 1,202 1,504
Mortality per 1,000 person years 2.9 3.8 4.6 5.2 6.9
Age-adjusted HR (95% CI) 1.00 1.15 (1.04–1.27) 1.34 (1.21–1.47) 1.48 (1.34–1.63) 1.87 (1.71–2.05) \0.001
Multivariable HR (95% CI)
a 1.00 1.06 (0.96–1.18) 1.17 (1.06–1.30) 1.24 (1.13–1.37) 1.42 (1.28–1.57) \0.001
CVD deaths
No. of cases 110 204 233 280 469
Mortality per 1,000 person years 0.5 0.9 1.0 1.2 2.1
Age-adjusted HR (95% CI) 1.00 1.61 (1.28–2.03) 1.69 (1.35–2.12) 1.95 (1.56–2.43) 3.27 (2.66–4.03) \0.001
Multivariable HR (95% CI)
a 1.00 1.37 (1.09–1.73) 1.28 (1.02–1.61) 1.34 (1.07–1.68) 1.77 (1.41–2.21) \0.001
IHD deaths
No. of cases 47 92 97 136 254
Mortality per 1,000 person years 0.2 0.4 0.4 0.6 1.2
Age-adjusted HR (95% CI) 1.00 1.70 (1.20–2.42) 1.65 (1.16–2.33) 2.23 (1.60–3.10) 4.17 (3.05–5.70) \0.001
Multivariable HR (95% CI)
a 1.00 1.40 (0.99–2.00) 1.19 (0.84–1.69) 1.43 (1.02–2.01) 2.02 (1.45–2.82) \0.001
Stroke deaths
No. of cases 34 62 74 81 109
Mortality per 1,000 person years 0.1 0.3 0.3 0.4 0.5
Age-adjusted HR (95% CI) 1.00 1.63 (1.07–2.48) 1.80 (1.20–2.70) 1.90 (1.27–2.84) 2.58 (1.75–3.79) \0.001
Multivariable HR (95% CI)
a 1.00 1.47 (0.96–2.23) 1.49 (0.99–2.25) 1.49 (0.99–2.25) 1.71 (1.13–2.59) 0.03
Abbreviations CI conﬁdence interval, CVD cardiovascular disease, HR hazard ratio, IHD Ischemic heart disease
a Adjusted for total cholesterol, systolic blood pressure, smoking, body mass index, menopausal status, time since meal, and physical activity
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deaths (P for trend 0.03 and \0.001, respectively). No
signiﬁcant interactions were found between triglycerides
and time since last meal, BMI, smoking, or cholesterol. No
substantial deviations from the proportional hazards
assumption were detected. The linearity assumption for
triglycerides was met for most models, except in men for
all cause and IHD deaths, and for CVD deaths in women.
Table 4 shows the change in the HR when adjusting
individually for each of the three major risk factors, cho-
lesterol, systolic blood pressure, and smoking. The relative
increase in risk associated with an increase of 1 mmol/l
triglyceride was higher in women than in men in both age-
adjusted and multivariable analyses. Adjusting for con-
founders reduced the HRs, and in men cholesterol was the
strongest confounder, whereas in women cholesterol, blood
pressure and smoking similarly changed the estimates.
Adjusting for regression dilution bias strengthens the effect
estimates. For example for IHD in women, age-adjusted
HR per 1 mmol/l triglyceride changes from 1.45 to 2.07 if
we adjust for regression dilution bias. The estimates given
in the tables are not adjusted for regression dilution bias.
The baseline characteristics of the sub-sample from
screening II with HDL-measurements are given in Table 5.
Mean follow-up was 24.8 years (range from 0.01 to 27.8).
Due to the study design, mean age at screening (Table 5)
and mean age at death was slightly higher in the sub-sam-
ple, i.e. 65.6 years (range 26.3–81.6). Women had higher
HDL-cholesterol levels than men. Compared to the main
study sample (Table 1), the subjects in the sub-sample
smoked less and were more physically active. By compar-
ing the different models with and without adjustment for
HDL-cholesterol, we see that the effect of triglycerides is
attenuated after adjustment, particularly in women
(Table 6). Additionally, the previous differences between
men and women were no longer present after inclusion of
HDL-cholesterol in the models. There is still a signiﬁcant
effect of triglycerides on all cause mortality in both men and
women, however, the association is considerably weaker
after multivariable adjustment (Table 6), suggestion resid-
ual confounding. No signiﬁcant interactions were found
between triglycerides and HDL-cholesterol.
The Framingham CHD risk scores were signiﬁcantly
associated with risk of death from CVD and IHD (Table 7).
Table 3 Association between triglycerides and risk of death from all causes, CVD, IHD, and stroke in 42,653 men in the main study sample (age
20–50 at baseline)
Quintile of nonfasting triglycerides, range (mmol/l) P for trend
12 3 4 5
0.21–1.10 1.11–1.47 1.48–1.93 1.94–2.64 2.65–19.35
No. of participants 8,548 8,386 8,689 8,477 8,553
All cause deaths
No. of cases 1,671 1,674 1,940 2,012 2,231
Mortality per 1,000 person years 7.3 7.4 8.4 9.1 10.2
Age-adjusted HR (95% CI) 1.0 0.95 (0.89–1.02) 1.04 (0.97–1.11) 1.12 (1.05–1.20) 1.28 (1.20–1.36) \0.001
Multivariable HR (95% CI)
a 1.0 0.89 (0.83–0.96) 0.94 (0.88–1.00) 0.96 (0.90–1.03) 0.99 (0.92–1.06) 0.43
CVD deaths
No. of cases 533 582 703 801 1.001
Mortality per 1.000 person years 2.3 2.6 3.0 3.6 4.6
Age-adjusted HR (95% CI) 1.00 1.04 (0.92–1.16) 1.17 (1.05–1.31) 1.39 (1.25–1.55) 1.78 (1.61–1.98) \0.001
Multivariable HR (95% CI)
a 1.00 0.92 (0.82–1.03) 0.96 (0.85–1.08) 1.03 (0.92–1.15) 1.07 (0.96–1.21) 0.03
IHD deaths
No. of cases 311 373 474 561 689
Mortality per 1,000 person years 1.4 1.7 2.0 2.5 3.2
Age-adjusted HR (95% CI) 1.00 1.14 (0.98–1.33) 1.37 (1.18–1.58) 1.68 (1.46–1.93) 2.11 (1.85–2.41) \0.001
Multivariable HR (95% CI)
a 1.00 1.00 (0.86–1.16) 1.09 (0.94–1.26) 1.20 (1.04–1.39) 1.21 (1.05–1.40) \0.001
Stroke deaths
No. of cases 102 99 113 105 124
Mortality per 1,000 person years 0.4 0.4 0.5 0.5 0.6
Age-adjusted HR (95% CI) 1.00 0.91 (0.69–1.19) 0.97 (0.74–1.26) 0.94 (0.71–1.23) 1.15 (0.89–1.50) 0.30
Multivariable HR (95% CI)
a 1.00 0.85 (0.64–1.12) 0.86 (0.66–1.13) 0.79 (0.59–1.05) 0.86 (0.65–1.15) 0.30
Abbreviations CI conﬁdence interval, CVD cardiovascular disease, HR hazard ratio, IHD ischemic heart disease
a Adjusted for total cholesterol, systolic blood pressure, smoking, body mass index, time since meal, and physical activity
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123The hazard ratio was unchanged after adjustment for tri-
glycerides, and triglycerides had no predictive value after
inclusion of the Framingham score in the model.
Discussion
In the Norwegian Counties Study nonfasting triglycerides
were positively associated with CVD death in both gen-
ders, with hazard ratios being higher in women than in
men. After adjustment for cholesterol, systolic blood
pressure and smoking, and in a sub sample also HDL-
cholesterol, the associations were distinctly attenuated.
After adjustment for the Framingham risk score, the posi-
tive association between triglycerides and mortality risk
disappeared.
Recent reports from two prospective studies have
described strong associations between postprandial tri-
glycerides and risk of CVD and stroke [7–9]. The Copenhagen
City Heart Study showed an independent effect of
nonfasting triglycerides on myocardial infarction, IHD, and
stroke, particularly in women [8, 9]. Accordingly, in the
Women’s Health Study nonfasting, but not fasting, levels
were associated with incident cardiovascular events in
females [7]. In the Copenhagen City Heart Study, the main
analyses were not adjusted for HDL-cholesterol, and thus
are comparable to our analyses on the total study sample.
For example for all cause deaths in women the age-
adjusted HRs per1 mmol/l increase in triglycerides were
1.27 and 1.26 in ours and the Danish study, respectively.
After multivariable adjustment the corresponding HRs
were 1.16 and 1.18. Comparable estimates were also found
for IHD and CVD. In the Women’s Health Study, on the
other hand, the association between triglycerides and risk
still persisted after adjustment for additional risk factors
including HDL-cholesterol [7]. Discrepancies between
univariate and multivariable analyses in studies on CVD
risk and triglycerides have been reported in many studies
[4, 7, 8]. Due to the strong negative correlation between
HDL-cholesterol and triglycerides, and to the differences in
Table 4 Risk of death from all
causes, CVD, IHD, and stroke
by a 1 mmol/l increase in
nonfasting triglyceride levels in
the main study sample (age
20–50 at baseline)
Abbreviations CI conﬁdence
interval, CVD cardiovascular
disease, IHD ischemic heart
disease
a Based on nonfasting
triglycerides on a continuous
scale
b Adjusted for total cholesterol,
systolic blood pressure,
smoking, body mass index,
menopausal status (women
only), time since meal, and
physical activity
Adjusted for age and: Hazard ratios (95% CI)
a
Women (n = 41,317) Men (n = 42,653)
All cause deaths n = 5,267 n = 9,528
None 1.27 (1.24–1.30) 1.10 (1.08–1.12)
Total cholesterol (mmol/l) 1.23 (1.20–1.27) 1.05 (1.03–1.07)
Systolic blood pressure (mm Hg) 1.24 (1.21–1.27) 1.08 (1.07–1.10)
Smoking (yes/no) 1.22 (1.19–1.25) 1.09 (1.07–1.10)
All three 1.17 (1.13–1.20) 1.03 (1.02–1.05)
Full model
b 1.16 (1.13–1.20) 1.03 (1.01–1.04)
CVD deaths n = 1,296 n = 3,620
None 1.40 (1.35–1.45) 1.17 (1.15–1.19)
Total cholesterol (mmol/l) 1.34 (1.28–1.39) 1.08 (1.06–1.11)
Systolic blood pressure (mm Hg) 1.35 (1.30–1.40) 1.14 (1.11–1.16)
Smoking (yes/no) 1.34 (1.29–1.39) 1.16 (1.13–1.18)
All three 1.24 (1.18–1.30) 1.05 (1.03–1.08)
Full model
b 1.20 (1.14–1.27) 1.03 (1.00–1.05)
IHD deaths n = 626 n = 2,408
None 1.45 (1.40–1.52) 1.19 (1.16–1.22)
Total cholesterol (mmol/l) 1.39 (1.32–1.46) 1.09 (1.06–1.12)
Systolic blood pressure (mm Hg) 1.41 (1.35–1.47) 1.15 (1.12–1.18)
Smoking (yes/no) 1.40 (1.34–1.46) 1.17 (1.14–1.20)
All three 1.29 (1.22–1.36) 1.05 (1.03–1.08)
Full model
b 1.26 (1.19–1.34) 1.03 (1.00–1.06)
Stroke deaths n = 360 n = 543
None 1.27 (1.15–1.40) 1.07 (1.00–1.14)
Total cholesterol (mmol/l) 1.22 (1.09–1.36) 1.03 (0.96–1.11)
Systolic blood pressure (mm Hg) 1.22 (1.10–1.35) 1.04 (0.98–1.11)
Smoking (yes/no) 1.21 (1.09–1.34) 1.06 (1.00–1.13)
All three 1.12 (0.99–1.26) 1.01 (0.94–1.08)
Full model
b 1.09 (0.96–1.23) 0.99 (0.92–1.07)
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123the measurement variability of these lipids, it has been
shown theoretically that by adjusting for HDL-cholesterol,
the triglyceride-disease association will be consistently
underestimated [4]. It is thus controversial whether HDL-
cholesterol should be included in multivariable models, as
also discussed in the two prospective studies described
above [7, 8].
It has been difﬁcult to demonstrate a possible causal
relationship between triglycerides and CVD by drug
intervention studies, as drugs that reduce triglycerides also
raise HDL-cholesterol [20]. Interestingly, a recent paper
addresses the question of causality by studying a genetic
polymorphism regulating triglyceride concentration [24].
The results from this collaborative analysis of 101 studies
indicate a causal association between triglyceride-mediated
pathways and coronary heart disease. Previous meta-anal-
yses report an increase in CHD risk of about 70% com-
paring high triglyceride levels with low triglyceride levels
Table 5 Baseline [Baseline
values are data from attendance
at screening II] characteristics
of the sub sample with HDL-
cholesterol from screening II
(age 20–55 at baseline)
Abbreviations BMI body mass
index, HDL high density
lipoprotein, SD standard
deviation
Women (n = 20,293) Men (n = 19,850)
Age, mean (SD) 44.7 (7.3) 44.6 (7.4)
Triglycerides, mean (SD), (mmol/l) 1.41 (0.78) 2.07 (1.14)
Total cholesterol, mean (SD), (mmol/l) 6.02 (1.19) 6.00 (1.11)
HDL-cholesterol, mean (SD), (mmol/l) 1.43 (0.34) 1.18 (0.31)
Systolic blood pressure, mean (SD), (mm Hg) 131 (18) 137 (16)
BMI, mean (SD), (kg/m
2) 24.4 (3.8) 25.2 (3.0)
Post-menopausal (%) 26.8 –
Smoking (%) 33.6 44.7
Physical inactivity (%) 14.9 13.7
Time since meal, mean (SD) 2.56 (0.92) 2.39 (1.01)
Table 6 Risk of death from all
causes, CVD, IHD, and stroke
by a 1 mmol/l increase in
nonfasting triglyceride levels in
the sub sample with HDL-
cholesterol from screening II
(age 20–55 at baseline)
Abbreviations CI conﬁdence
interval, CVD cardiovascular
disease, HDL high density
lipoprotein, IHD ischemic heart
disease
a Based on nonfasting
triglycerides on a continuous
scale
b Multivariable adjustments for
total cholesterol, HDL-
cholesterol, systolic blood
pressure, smoking, body mass
index, menopausal status
(women only), time since meal,
and physical activity
Adjusted for age and: Hazard ratios (95% CI)
a
Women (n = 20,293) Men (n = 19,850)
All cause deaths n = 2,827 n = 4,747
None 1.19 (1.15–1.24) 1.10 (1.08–1.13)
HDL-cholesterol (mmol/l) 1.15 (1.10–1.20) 1.11 (1.08–1.13)
Cholesterol, systolic blood pressure, and smoking 1.11 (1.06–1.16) 1.06 (1.03–1.08)
All four 1.07 (1.02–1.12) 1.06 (1.03–1.09)
Full model
b 1.06 (1.01–1.12) 1.06 (1.03–1.09)
CVD deaths n = 709 n = 1,734
None 1.37 (1.28–1.46) 1.21 (1.17–1.26)
HDL-cholesterol (mmol/l) 1.25 (1.16–1.35) 1.18 (1.14–1.23)
Cholesterol, systolic blood pressure, and smoking 1.19 (1.10–1.28) 1.12 (1.08–1.16)
All four 1.06 (0.97–1.16) 1.07 (1.03–1.12)
Full model
b 1.03 (0.94–1.13) 1.06 (1.01–1.11)
IHD deaths n = 344 n = 1,143
None 1.44 (1.32–1.57) 1.24 (1.19–1.29)
HDL-cholesterol (mmol/l) 1.29 (1.16–1.43) 1.18 (1.13–1.24)
Cholesterol, systolic blood pressure, and smoking 1.20 (1.09–1.33) 1.12 (1.07–1.17)
All four 1.02 (0.90–1.15) 1.04 (0.99–1.09)
Full model
b 0.99 (0.88–1.13) 1.03 (0.97–1.08)
Stroke deaths n = 195 n = 278
None 1.33 (1.17–1.51) 1.07 (0.97–1.19)
HDL-cholesterol (mmol/l) 1.19 (1.02–1.39) 1.07 (0.96–1.19)
Cholesterol, systolic blood pressure, and smoking 1.23 (1.07–1.42) 1.05 (0.95–1.17)
All four 1.10 (0.92–1.30) 1.04 (0.93–1.17)
Full model
b 1.10 (0.92–1.31) 1.05 (0.93–1.18)
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123[2, 3]. However, it is probably not the nonfasting triglyc-
erides per se that cause atherosclerosis, but rather the
cholesterol content of remnant lipoproteins [8, 21]. Rem-
nant lipoproteins arise after lipolysis of chylomicrons and
VLDL, the two classes of lipoproteins whose major lipid is
triglyceride [22]. The remnant particles are under normal
conditions rapidly taken up by the liver [22]. Hepatic
removal of the remnant particles are, however, a complex
process, and in people with a predisposition of producing
remnant particles or small dense LDL and HDL particles,
people with metabolic syndrome or type 2 diabetes, hepatic
clearance of remnant particles can be delayed [8, 22, 23].
Thus, prolonged exposure of increased levels of circulating
remnant particles will enhance the possibility for the par-
ticles to be entrapped in the arterial wall. Accordingly,
remnant lipoproteins have been shown to increase risk of
atherosclerotic heart disease [23]. A strong correlation
between nonfasting triglycerides levels and remnant lipo-
protein cholesterol has been shown [8], and this may
account for the stronger associations of nonfasting levels of
triglycerides with CVD [7]. One cannot exclude, however,
that the association between nonfasting triglycerides levels
and cardiovascular risk observed in our and previous
studies in part could be a result of residual confounding by
unmeasured confounders.
The ﬁnding of stronger effects of nonfasting triglycer-
ides among women than men in our and previous studies
[8, 9, 11], are not easily explained. A gender dependent
difference in risk has also been shown for fasting triglyc-
erides [1, 4, 25], however, data are not consistent [2, 3].
The Framingham risk score includes HDL-cholesterol
[18], and adjusting for HDL-cholesterol or the Framingham
risk score attenuated the effect of triglycerides in the
present study. Accordingly, a recent study including data
from 112 prospective studies concluded that lipid assess-
ment could be simpliﬁed by measurement of nonfasting
lipids, either total cholesterol and HDL-cholesterol or
apolipoproteins, without regard to triglycerides [26]. Thus
the role for triglycerides as an independent risk factor is
still controversial.
The Norwegian Counties Study has several strengths.
First, the mortality in the three counties under study, were
found to be similar to the national levels [27], and as the
attendance was high (84–88%), we argue that this study
sample is representative of Norway. Our study sample is of
considerable size, and has a long and complete follow-up.
It is noted that the power to detect a hazard ratio of 1.06 at
the 5% level, varies from[0.9 in men (all cause deaths) to
0.2 in women (stroke deaths). For IHD deaths the power is
0.6 in women and 0.9 in men. Thus, for some endpoints, we
have sufﬁcient power to reveal even small effects.
A major limitation is that we do not have data on
exposure after 1988. Due to the long follow-up time, a
considerable number of individuals might have started with
medications affecting triglycerides levels. We could not
adjust for alcohol or hormone therapy, however, no dif-
ferences in CVD mortality between users and non-users of
hormone therapy have previously been reported in women
from screening III [28].
In summary, we observed a stronger association
between nonfasting triglycerides and risk of cardiovascular
death in women than in men. The effect, was, however,
attenuated after adjustment for HDL-cholesterol or
adjustment for Framingham risk. Lastly, nonfasting tri-
glycerides add no predictive information of CVD risk
beyond the Framingham CHD risk score.
Table 7 Risk of death from
CVD and IHD in the sub sample
with calculated Framingham
risk score from screening II (age
40–55 at baseline)
Abbreviations CI conﬁdence
interval, CVD cardiovascular
disease, IHD ischemic heart
disease
a Based on nonfasting
triglycerides on a continuous
scale
All models adjusted for age
Hazard ratios (95% CI)
a
One variable at
a time in model
Both variables
in model
Women (n = 16,805)
CVD deaths (n = 691)
Triglycerides (per 1 mmol/l) 1.36 (1.28–1.46) 0.97 (0.89–1.06)
Framingham (per 1 unit) 1.11 (1.10–1.12) 1.11 (1.10–1.13)
IHD deaths (n = 335)
Triglycerides (per 1 mmol/l) 1.43 (1.31–1.56) 0.96 (0.85–1.08)
Framingham (per 1 unit) 1.13 (1.11–1.14) 1.13 (1.11–1.15)
Men (n = 16,318)
CVD deaths (n = 1,657)
Triglycerides (per 1 mmol/l) 1.22 (1.18–1.26) 1.02 (0.98–1.07)
Framingham (per 1 unit) 1.08 (1.07–1.08) 1.08 (1.07–1.08)
IHD deaths (n = 1,092)
Triglycerides (per 1 mmol/l) 1.25 (1.19–1.29) 1.01 (0.96–1.07)
Framingham (per 1 unit) 1.09 (1.08–1.10) 1.09 (1.08–1.10)
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